chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Shoulder blade and chest muscle was hurting very bad. She stated she couldn't lay on her right side. Saw pcp on Nov 12th and she told her it was from the shot being given to high in the arm.
ED to Hosp-Admission Discharged  3/28/2021 - 3/30/2021 (2 days)    Last attending ? Treatment team Weakness Principal problem Discharge Summary DO (Physician) ? ? Internal Medicine           Discharge Summary   Hospitalist Medicine      Date: 3/30/2021 Admission Date: 3/28/2021 Length of Stay: 2 Days  Discharge Date: 3/30/2021     Admission Diagnosis     Hospital Problems          POA   * (Principal) Weakness Yes       Hypothyroidism Yes       Pure hypercholesterolemia Yes       Benign essential hypertension Yes       Atrial fibrillation  Yes       Acute cystitis without hematuria Yes       Generalized weakness Yes       COVID-19 virus infection Yes       Chronic respiratory failure with hypoxia  Yes            Home Under Care of a company unnamed   CODE STATUS: Full Code     Active Issues Requiring Follow-up     Finish course of antibiotics.  Participating remote monitoring.     Test Results Pending at Discharge     Pending Labs    Order Current Status   Blood culture Preliminary result   Blood culture Preliminary result         Hospital Course     HPI:  Patient is a 89 y.o. female with PMH listed who presents from home with her daughter complaining of about a week of increased weakness/fatigue and cough.  The fatigue is their primary concern, as this is so profound she will fall asleep on the toilet or even in the middle of getting dressed.  Appetite is decreased, but she denies N/V/D.  She feels "chilled", but no known fevers, no rigors/sweats.  Cough is occasionally productive of sputum, mostly clear but sometimes with small "chunks"; no hemoptysis.  No LE edema.  No HA or changes in taste/smell.  No known sick contacts, but patient has exposure to multiple daughters who help care for her, and she has been attending church recently.  Urine is dark/strong, but she denies dysuria.   Pt has received both doses of COVID-19 vaccine, second dose on 3/17/21.   Hospital Course:    Patient was admitted to medical floor for COVID-19 infection and urinary tract infection.  Patient had a very mild course of illness.  Decadron was started but patient did not require any remdesivir.  Patient has remained at her seen home oxygen requirement.  Patient was seen by PT and OT services for generalized weakness.  Blood cultures have been negative.  Patient is medically stable for discharge home today.  She will need another 2 days of antibiotics treatment for urinary tract infection.  Since her respiratory status has been very stable, we have chosen to discontinue the use of Decadron upon discharge to avoid any changes in mental status induced by steroids in an elderly patient.  Home health services and remote monitoring kit have been ordered at the time of discharge.   I have called patient's daughter  to provide update that patient is coming home today and answered her questions
Pt c/o fever and body aches, pt taking Tylenol/Ibuprofen. Redness, swelling and tenderness to injection site.
Patient received COVID-19 vaccine. AFter 5 minutes of observation she got itchy and started getting a red rash on her throat area. She was very calm and asked for help. Paramedics noticed she was turning discolored and provided Benadryl p.o 4mL. They asked to transport her to a nearby hospital and she agreed. They were in transport at 4:35pm to the hospital to get her treatment for adverse reaction.
Dizziness, Diaphoretic, Fainting, Decreased BP, Decreased HR. Pt remained in health dept for approx. 1hr 15 min. Pt was transferred to ER via ambulance at 12:35 (2nd time EMS came) EMS called at the initial time, evaluated by EMS, then EMS left. Recalled at 12:21pm for symptoms not improving and patient with severe headache at 12:09. Pt received bloodwork and CT scan at ER.
about 12 hours after the immunization, the patient noticed some discoloration areas on the underside of the left arm (same arm that he got the vaccine). He only noticed it when going to put on a shirt, as it did not hurt or itch. He said he did vomit one time about 24 hours after receiving the vaccination and felt light headed at that time.
Information has been received from a nurse practitioner concerning a 15 year old female who, on an unspecified date, was vaccinated with her first dose of GARDASIL (Lot # and site not reported).  The patient experienced redness and itching around the injection site.  On an unspecified date the patient was vaccinated with her second dose of GARDASIL (Lot # and site not reported).  Subsequently the patient experienced redness, itching, and hives following her second dose of GARDASIL.  The patient sought unspecified medical attention.  Additional information has been requested.   This is in follow-up to report(s) previously submitted on 4/14/2008.  Follow-up information received on 05-MAY-2008 from the physician reported that the office has no information.  The experiences was brought to their attention by the patient's father after the fact and there was "no objective findings".  No additional information was reported.  Additional information is not expected.
Pain, redness, swelling, and warmth at the injection site.  Recommended OTC pain releivers (APAP and ibuprofen), cool compress for immediate treatment and referred to PCP for follow up for concerns of cellulitis
Rash, Blister, Fever, Skin Lesion, Pruritus, Fustule - Information has been received from a registered nurse concerning a 7 year old white female student with sulfunamide allergy who on 25 Apr 2000 was vaccinated with the first dose of varicella virus vaccine live (632612/1851j) in the right arm.  On 11 May 2000 the patient developed a rash on her chest that looked like little pinpoints littel pustules, and some little vesicles.  The reporter indicated that the patient had 6-8 lesions around one nipple and 10-12 lesions around the other and a slight fever of 99.6 F.  The reporter also indicated that the rash was itchy, the patient sought unspecified medical attention.  follow up information was received on 21 Aug 2000 from a registered nurse indicated that on 11 May 2000 the patient came into the school clinic with a rash.  The nurse's concern was whether the patient was contagious to other students at school if the rash was caused by the varicella virus vaccine live.  The rash appeared somewhat similiar to chickenpox and occurred aproximately three weeks after receiving varicella virus vaccine live.  The patient did not appear ill and said her mom had already seen the rash.  The patient came to the school clinic with the chief compaint of itching.  It was noted that the patient had skin lesions, itchy rash, vesicles, pustules and a 99.6 degree oral temperature.  The patient was not in distress.  On an unspecified date. the patient recovered.
Right arm pain that began 2 hours after injection Lightheaded, nausea, fatigue that began 16 hours after injection. Lightheaded and nausea symptoms decreased after 2 hours but fatigue lasted 24 hours. Right arm pain is still present but diminished after 36 hours. Alternating 1000 mg Acetaminophen and 800 mg Ibuprofen q3h for 15 hours once symptoms started.
sick; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Pro. The reporter is the patient.  An elderly male patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ILLNESS (non-serious), outcome "unknown", described as "sick". Additional information: How sick I was back then when I got the vaccine.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
DIZZINESS; HEADACHE (RIGHT ON TEMPLES); SLEEPINESS; FEELING LIKE FLU; NO ENERGY; This spontaneous report received from a patient concerned a 62 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included alcohol user.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: unknown) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. The company is unable to perform follow up to request batch/lot number. No concomitant medications were reported. On APR-2021, the subject experienced sleepiness. On APR-2021, the subject experienced feeling like flu. On APR-2021, the subject experienced no energy. On 10-APR-2021, the subject experienced dizziness. On 10-APR-2021, the subject experienced headache (right on temples). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from dizziness on APR-2021, had not recovered from headache (right on temples), and the outcome of no energy, sleepiness and feeling like flu was not reported. This report was non-serious.
This spontaneous case report was received from a 60-year-old male patient regarding himself. The patient's medical history and drug allergies were none. On 13-DEC-2015, the patient was vaccinated with ZSOTAVAX (lot number and expiry date unknown) (dosing regimen, dose number, anatomical location and strength) for shingles. Concomitant medications were none. On 13-DEC-2015 an hour after vaccination with ZOSTAVAX, the patient experienced discomfort around vaccination site. On 15-DEC-2015, the patient checked on his arm and noticed that the becomes red and bump. The patient did not sought medical attention and no treatment was provided for the events. The outcome of the events was reported as not recovered. The relatedness of the events with ZOSTAVAX was not provided. No product quality complaint was reported. Additional information has been requested.
Took Shingrix vaccine, have shingles/ Suspected vaccination failure; shingles; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not reported. The reporter stated that, took the Shingrix vaccine in 2019, and had two eruptions of shingles since. The reporter was wondering if there was a study with a possible booster for the vaccine. This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles were not provided.
This case was reported by a consumer via sales rep and described the occurrence of pain in arm in a 62-year-old female patient who received SHINGRIX for prophylaxis. On 1st August 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a week after receiving SHINGRIX, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved. It was unknown if the reporter considered the pain in arm to be related to SHINGRIX. Additional details were provided as follows: This case was reported by the patient herself. The age at vaccination was not reported, but could be 61 years or 62 years. In August 2018, the patient experienced sore arm for 1 week. No other local reactions or general adverse events were experienced.
72 hours fever,  and headache migraine 3 days, injection spot swelled  three times normal...inch above normal skin, 3 weeks mono like sleepinnes, cough for two weeks, ab pain day 6  for three day
Huge red mark on right arm below the vaccination. Began small the next day, has been getting worse every day since.  Now, a WEEK later it is even larger, painful and have even begun to get better. (I have pics from Monday and again today.) She had a fever that did go away the next day. She totally lost her appetite for 5 days and would barely drink anything at all.
Developed a  dry cough within 10-15 min of receiving vaccine. This was followed by heart racing. No swelling or difficulty breathing but cough did progress and patient developed slight stridor. Symptoms were felt to be progressing so patient was admitted to the emergency department for evaluation.
Cold chills Friday afternoon and night(but consider those the mild side effects) Saturday morning noticed: dizziness with movement(like motion sickness); nausea has continued since then(Sat, Sun, Mon, Tues, Wed) Dizziness has been severe and causing nasea with gagging but not vomiting.  Feeling off balance, using walls etc in order to walk straight. Blurred vision (comes and goes as dizziness increases/decreases)  Difficulty concentrating.   Yesterday(Tuesday) pulling sensation down right side of neck, confusion, blurred vision.  Slight hesitation to writing with right hand(had to concentrate to sign my name etc)
Patient had a rash on LEs & abdomen.  He described it as painful & itchy.  Benadryl & Hydrocortisone cream were administered.  He f/u with his PCP.
Pt 7/22/2007 received Pfizer vaccination on 8/19 reported filling lightheaded and then passed out. Mom was present and called 911  Pt  was placed on the floor  by technician and came too shortly after we proceeded to talk with pt, monitored BP and provided pt with water until 911 arrived.  Pt was able to sit up in a chair and was evaluated by EMS and was better and did not have to be taken by EMS.
This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown demographics. Patients pertinent medical history, concurrent condition and concomitant medication were not reported. No previous drug reactions/allergies were reported. On unknown dates, these patients were vaccinated with improperly stored doses of GARDASIL 9 (lot # L019297, expiry date 18-AUG-2017 and lot# M007764, expiry date 30-JAN-2018) (strength, dosing details, anatomical location were unknown). The vaccine had been stored at 8.1 degrees Celsius for 15 minutes, and also at 8.3 degree Celsius for 15 minutes. The temperature excursion was detected by a data logger. No adverse effects were reported. No product quality complaint was involved. This is one of the several reports received from the same reporter. Additional information is not expected as the reporter did not wish to be contacted.
Within 2 minutes of receiving vaccine, pt stated she felt faint. Periodic bedrest x 20" BP 120/80 P 88 R 18.
This spontaneous report received from a registered nurse referred to a 1 year old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 27-MAR-2017, the patient was vaccinated with VARIVAX (dose, frequency not reported, lot:M028546, expiry date not reported) for an unspecified indication. The nurse reported that the vaccines were stored in a freezer with defrost cycles, but full excursion details were not provided (incorrect product storage). The reason for the temperature excursion occurred was due to the defrost cycle of the freezer. The nurse was unable to provide the lot number and expiration date for the properly stored sterile diluent that may have been used to reconstitute the vaccine. No adverse effects reported. The temperature for the vaccine stored and time frame was unspecified. Previous temperature excursion was unspecified. Data logger was involved. This is one of the several reports received from the same reporter. Additional information has been requested.
seem to have lost some sense of smell and getting light headed or dizzy foggy feelings and a little ache in back
pt recv vax 7FEB96 & pt 7MAR98 pt devel approx 400 lesions including in or near eye;pt required a visit of ophthalmologist;
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 54-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: FLONASE ALLERGY RELIEF; ZYRTEC ALLERGY. The following information was reported: DRUG INEFFECTIVE (medically significant), SARS-COV-2 TEST POSITIVE (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: COVID 19 Treatment; (21Jul2022) Positive, notes: days after first dose of Paxlovid, felt better and tested barely positive; (23Jul2022) Positive, notes: 11 days after first dose, started having symptoms and tested very positive; (30Jul2022) Positive, notes: 18 days after first dose of Paxlovid, still symptomatic and testing very positive. Therapeutic measures were taken as a result of drug ineffective, sars-cov-2 test positive.   Clinical course: The patient took other medication in 2 weeks which included Flonase, one a day vitamin, Zyrtec and saline nose spray. The patient received Paxlovid, start date:12Jul2022; stop date:17Jul2022 as treatment for adverse events. The patient had no known allergies.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Did not feel well; Had a fever that evening; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (Did not feel well) and PYREXIA (Had a fever that evening) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 030L20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high and Overweight. Concomitant products included LISINOPRIL for Blood pressure high.   On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Mar-2021, the patient experienced MALAISE (Did not feel well) and PYREXIA (Had a fever that evening). On 02-Mar-2021, MALAISE (Did not feel well) and PYREXIA (Had a fever that evening) had resolved.            No treatment medications were reported.   This case was linked to MOD-2021-294162 (Patient Link).
This was my 2nd dose of the Moderna vaccine. I did not have any symptoms other than a sore arm on my first dose, however, I developed hives and 3 rashes with my 2nd dose 2 days after the injection. I started scratching my neck when I drove away from the health clinic and took a Benadryl as soon as I could but no rash appeared at that time. The major rash developed on my neck and felt like and looked like  a severe sunburn. I contacted a virtual healthcare company on day 3 and included a photo of my neck and symptoms. The doctor called me and gave me an evaluation on the phone and she said I probably had a reaction form the vaccine.
4-1-21-headache, indigestion, 4-2-21 ER visit, with admission, R/O MI. 4-3-21 transferred via ambulance for pulmonary embolism almost occluding pulmonary artery with peripheral and additional pulmonary clots. Performed thrombectomy immediately on arrival to hospital.  Then 48 hours heparin therapy, home on Eliquis
This spontaneous report was received from a healthcare worker concerning a patient of unknown age and gender. On an unknown date, the patient was vaccinated with a dose of PNEUMOVAX 23 (lot number and expiry date were reported as J004747 and 20-JUL-2014 respectively, dose and route unspecified). No concomitant therapy was reported. On an unknown date, the patient developed cellulitis after receiving one dose of PNEUMOVAX 23. It was unspecified if the patient sought any medical attention. The outcome of cellulitis was unknown. The relatedness for cellulitis was unknown for PNEUMOVAX 23. The healthcare worker requested lot check on behalf of physician. This is one of the two reports from the same source. Additional information has been requested.
Report 2001028745-1 describes an injection site reaction in a 4 year old female who received Infanrix. Medical history, concurrent conditions, and concurrent medications were not specified. On 11/26/2001, the vaccinee received her first injection of Infanrix. On that date, she also received injection of IPOL and MMR vaccines. On 11/28/2001, two days post-immunization, she experienced an injection site reaction characterized by a red, four-inch lump that was hot to the touch. No medical attention was needed. The vaccine provider considered the events to be mild in intensity and related to Infanrix administration. As of 12/03/2001, the events had resolved.
about three hours after adminstration severe chills, fever (100), weakness and muscle aches and headache and nausea  -- took fluids tylenor and advil and fever and chills subsided around midnight and just have residual body aches, and muscle weakness
Fever of 101.6, chills, nausea, joint and muscle pain, fatigue. Lasted from 8pm on 11/9 through the day of 11/10.  Treatment is Tylenol.
Patient reports erythema to L arm followed by muscle soreness and itching. There is induration noted approx 7cm. Patient reports reaction 10/17/06 around 5pm but states she applied topical cortisone to area for relief of itching. 10/18/06 am she noted that there was redness and edema to site with area warm to touch.  Area was assessed, no broken skin noted, and patient is afebrile (and has been throughout symptoms). Oral antihistamine (Claritin) given and area was assessed bid. Patient was asked to take oral Benadryl at bedtime and area will be reassessed in am. Advised to contact Employee Health for any other symptoms or concerns.
received an expired dose; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 4-year-old female patient who received DTPa-IPV (Kinrix) (batch number 30Z45, expiry date 15th January 2022) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 17th January 2022, the patient received Kinrix (intramuscular) and Kinrix Pre-Filled Syringe Device. On 17th January 2022, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not reported but it could be 3 or 4 years. The patient inadvertently received an expired dose of Kinrix in the right thigh, which led to expired vaccine used. The reporter consented to follow up.
Swelling Pt received flu shot on 9/16 in left deltoid after immunization pt experienced itching at site. On 9/17 pt experienced body aches and lethargy. On 9/18 pt noticed swelling in lymph nodes under right arm and pain in elbow and hand.
Narrative:  71 year old patient with history of metastatic esophageal cancer complicated by liver mets, associated ascites, and malignant pain who had been admitted to facility for hospice/end of life care. Received second dose of vaccine over a month before passing. No indication that event was due to vaccine.
On 5/18/01, the pt developed petechiae and ecchymosis. Platelet count was 2000. Diagnosed with thrombocytopenia.